Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases

Nanomedicine

Volumn 5, Issue 9, 2010, Pages 1435-1445

  Kanwar, Jagat R ^a   Mohan, Rajiv R ^b,c   Kanwar, Rupinder K ^a   Roy, Kislay ^a   Bawa, Raj ^d,e  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MISSOURI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Research Rensselaer Polytechnic Institute   (United States)

^e Bawa Biotechnology Consulting LLC   (United States)

Author keywords

aptamer; cancer; inflammatory disease; nano delivery; SELEX

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; APTAMER; BEVACIZUMAB; DICLOFENAC; DIQUAFOSOL; PEGAPTANIB; SEMAXANIB;

CANCER DIAGNOSIS; DIGESTIVE SYSTEM INJURY; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ERUPTION; EDEMA; EYE DISEASE; HEADACHE; HEART INFARCTION; HUMAN; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; KIDNEY INJURY; LIVER INJURY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; APTAMERS, NUCLEOTIDE; APTAMERS, PEPTIDE; EYE DISEASES; HUMANS; INFLAMMATION; MICE; NANOTECHNOLOGY; NEOPLASMS;

EID: 78650073758     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.115     Document Type: Review

References (65)

1. Gunter M, Jenne A: Aptamers in research and drug development. BioDrugs 18(6), 351-359 (2004).
2. James W: Aptamers. Encyclopedia of Analytical Chemistry 4848-4871 (2000).
3. Kaur G, Roy I: Therapeutic applications of aptamers. Expert Opin. Investig. Drugs 17(1), 43-60 (2008).
4. Ray P, White RR: Aptamers for targeted drug delivery. Pharmaceuticals 3(6), 1761-1778 (2010).
5. Fang X, Tan W: Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc. Chem. Res. 43(1), 48-57 (2010).
6. Rimmele M: Nucleic acid aptamers as tools and drugs: recent developments. Chem. Bio. Chem. 4(10), 963-971 (2003).
7. Bouchard PR, Hutabarat RM, Thompson KM: Discovery and development of therapeutic aptamers: annual review of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. (50), 237-257 (2010).
8. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specifc ligands. Nature 346(6287), 818-822 (1990).
9. Romig TS, Bell C, Drolet DW: Aptamer affnity chromatography: combinatorial chemistry applied to protein purifcation. J. chromatogr. B. Biomed. Sci. Appl. 731(2), 275-284 (1999).
10. Huang CJ, Lin HI, Shiesh SC, Lee GB: Integrated microfuidic system for rapid screening of CRP aptamers utilizing systematic evolution of ligands by exponential enrichment (SELEX). Biosens. Bioelectron. 25(7), 1761-1766 (2010).
11. Sampson T: Aptamers and SELEX: the technology. World Patent Information. 25(2), 123-129 (2003).
12. Mendonsa SD, Browser MT: In vitro selection of high affnity DNA ligands for human IgE using capillary electrophoresis. Anal. Chem. 76(18), 5387-5392 (2004).
13. Paul AAM, Ziemer CWN, Wendel HP: Upgrading SELEX technology by using lambda exonuclease digestion for single-stranded DNA generation. Molecules 15(1), 1-11 (2010).
14. Strehlitz B, Nikolaus N, Stoltenburg R: Protein detection with aptamer biosensors. Sensors 8(7), 4296-4307 (2008).
15. Klevenz B, Butz K, Seyler FH: Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its infuence on target protein binding. Cell. Mol. Life Sci. 59(11), 1993-1998 (2002).
16. Estévez MC, Huang YF, Kang H et al.: Nanoparticle-aptamer conjugates for cancer cell targeting and detection. Methods Mol. Biol. (624), 235-248 (2010).
17. Lee JH, Yigit MV, Mazumdar D, Lu Y: Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv. Drug Deliv. Rev. 62(6), 592-605 (2010).
18. Mahidhara G, Kanwar RK, Kanwar JR: A novel nanoplatform for oral delivery of anti-cancer biomacromolecules. Int. J. Nanotechnol. 2010 (In press).
19. Tong R, Coyle VJ, Tang L, Barger A, Fan TM, Cheng J: Polylactide nanoparticles containing stably incorporated cyanine dyes for in vitro and in vivo imaging applications. Microsc. Res. Tech. 73(9), 901-909 (2010).
20. Kim E, Jung Y, Choi H et al.: Prostrate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31(16), 4592-4599 (2010).
21. Chen CK, Huan CC, Chang HT: Label-free colorimetric detection of picomolar thrombin in blood plasma using a gold nanoparticle-based assay. Biosens. Bioelectron. 25(8), 1922-1927 (2010).
22. Javier DJ, Nitin N, Levy M, Ellington A, Kortum RR: Aptamer-targeted gold nanoparticles as molecular-specifc contrast agents for refectance imaging. Bioconjug. Chem. 19(6), 1309-1312 (2008).
23. Yoo MK, Kang SK, Choi JH, Park IQ: Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. Biomaterials 31(30), 7738-7747 (2010).
24. Liu Y, Wang P, Sun C et al.: Wheat germ agglutinin grafted lipid nanoparticles: preparation and in vitro evaluation of the association with Caco-2 monolayers. Int. J. Pharm. 397(1-2), 155-163 (2010).
25. Benny O, Fainaru O, Adini A et al.: An orally-delivered small molecule formulation with anitangiogenic and anticancer activity. Nat. Biotechnol. 26(7), 799-807 (2008).
26. Yoshikawa T, Okada N, Oda A et al.: Nanoparticles built by self-assembly of amphiphillic [g]-PGA can deliver antigens to antigen-presenting cells with high effciency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26(10), 1303-1313 (2008).
27. Ng EW, Adamis AP: Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY. Acad. Sci. (1082), 151-171 (2006).
28. Ciulla TA, Rosenfeld PJ: Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 20(3), 158-165 (2009).
29. Kourlas H, Schiller DS: Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin. Ther. 28(1), 36-44 (2006).
30. Wu PC, Yang LC, Kuo HK et al.: Inhibition of corneal angiogenesis by local application of vasostatin. Mol. Vis. 13(11), 28-35 (2005).
31. Pastor F, Kolonias D, Giangrande PH, Giloba E: Induction of tumor immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465(7295), 227-231 (2010).
32. Farokhzad OC, Jon S, Khademhosseini A, Naga T T, Lavan DA, Langer R: Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64(21), 7668-7672 (2004).
33. Pieve CD, Perkins AC, Missailidis S: Anti-MUC1 aptamers: radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice. Nucl. Med. Biol. 36(6), 703-710 (2009).
34. Mori T, Oguro A, Ohtsu T, Nakamura Y: RNA aptamers selected against the receptor activator of NF-kB acquire general affnity to proteins of the tumor necrosis factor receptor family. Nucl. Acids Res. 32(20), 6120-6128 (2004).
35. Leu SY, Jeong S: In vitro selection and characterization of TCF-1 binding RNA aptamers. Mol.Cells. 17(1), 174-179 (2004). (Pubitemid 39137063)
36. Fang X, Sen A, Vicens M, Tan W: Synthetic DNA aptamers to detect protein molecular variants in a high-throughput fuorescence quenching assay. Chem. Bio. Chem. 4(9), 829-834 (2003).
37. Jamal A, Tiwari RC, Murray T et al.: Cancer statistic: 2004. CA Cancer J. Clin. 54(1), 8-16 (2004).
38. Esteller M: Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
39. Li Z, Huang P, He R et al.: Aptamer-conjugated dendrimer-modifed quantum dots for cancer cell targeting and imaging. Materials Letters 64(3), 375-378 (2010).
40. Chiu TC, Huang CC: Aptamer-functionalized nano-biosensors. Sensors 9(12), 10356-10388 (2009).
41. 2+ detection. J. Am. Chem. Soc. 126(39), 12298-12305 (2004).
42. Liu J, Lu Y: Stimuli-responsive disassembly of nanoparticle aggregates for light-up colorimetric sensing. J. Am. Chem. Soc. 127(36), 12677-12683 (2005).
43. 2+) in aqueous media using DNA-functionalized gold nanoparticles. Angew. Chem. Int. Ed. 46(22), 4093-4096 (2007).
44. Wang H, Wang Y, Jin J, Yang R: Gold nanoparticle-based colorimetric and turn on fuorescent probe for mercury (II) ions in aqueous solution. Anal. Chem. 80(22), 9021-9028 (2008).
45. Wang Z, Lee JH, Lu Y: Label-free colorimetric detection of lead ions with a nanomolar detection limit and tunable dynamic range by using gold nanoparticles and DNAzyme. Adv. Mater. 20(17), 3263-3267 (2008).
46. Zhang L, Radovic AFM, Alexis F et al.: Co-delivery of hydrophobic and hydrophillic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem. 2(9), 1268-1271 (2007).
47. Bagalkot V, Zhang L, Nissenbaum LE et al.: Quantum dot-aptamer conjugate for synchronous cancer imaging, therapy and sensing of drug delivery based on bi-fuorescence resonance energy transfer. Nanolett. 7(10), 3065-3070 (2007).
48. Wang AZ, Bagalkot V: Superparamagnetic iron oxide-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chemmedchem. 3(9), 1311-1315 (2008).
49. Huang YF, Lin YW, Lin ZH, Chang HT: Aptamer-modifed gold nanoparticle for targeting breast cancer cells through light scattering, J. Nanopart. Res. 11(4), 775-783 (2009).
50. Cousseus LM, Werb Z: Infammation and cancer. Nature 420(6917), 860-867 (2002).
51. Platten M, Ho PP, Steinman L: Anti-infammatory strategies for the treatment of multiple sclerosis-tryptophan catabolites may hold the key. Drug Discov Today: Ther. Strateg. 3(3), 401-408 (2006).
52. Joeng CB, Niazi JH, Lee SJ, Bock M: SS DNA aptamer that recognizes diclofenac and 2-anilinophenylacetic acid. Bioorg. Med. Chem. 17(15), 5380-5387 (2009).
53. Shahrara S, Proudfoot EI, Park C et al.: Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J. Immunol. 180(5), 3447-3456 (2008).
54. Foster A, Resnikoff S: The impact of vision 2020 on global blindness. Eye (Lond.) 19(10), 1133-1135 (2005).
55. Wilson SE, Mohan RR et al.: The wound healing response after LASIK and PRK: elusive control of biological variability: vision correction. Arch. Ophthalmol. 119(6), 889-896 (2001).
56. Netto MV, Mohan RR, Sinha S, Sharma A, Dupps W, Wilson SE: Stromal haze, myofbroblasts, and surface irregularity after PRK. Exp. Eye Res. 82(5), 788-797 (2006).
57. Imanishi J, Kamiyama K, Iguchi I, Sotozono C, Kinoshita S: Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog. Retin. Eye Res. 19(1), 113-129 (2000).
58. Wilson SE, Mohan RR, Hutcheon EK et al.: Effect of ectopic epithelial tissue within stroma on apoptosis, mitosis, and myofbroblast transformation. Exp Eye Res. 76(2), 193-201 (2003).
59. Jester J V, Lane BPA, Petroll WM, Olsen DR, Cavanagh HD: Inhibition of corneal fbrosis by topical application of blocking antibodies to TGF b in the rabbit. Cornea 16(2), 177-187 (1997).
60. Rodrigues EB, Farah ME, Maia M: Therapeutic monoclonal antibodies in ophthalmology. Prog. Retin. Eye Res. 28(2), 117-144 (2009).
61. Bock F, Onderka J, Rummelt C: Safety profle of topical VEGF neutralization at the cornea. Invest. Ophthalmol. Vis. Sci. 50(5), 2095-2102 (2009).
62. Cursiefen C, Bock F, Horn FK: GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized Phase II trial. Ophthalmology 116(9), 1630-1637 (2009).
63. Yoeruek E, Ziemssen F, Fahle HS et al.: Safety, penetration and effcacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 86(3), 322-328 (2008).
64. Zhang Z, Ma JX, Gao G et al.: Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 46(11), 4062-4071 (2005).
65. Apte RS: Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin. Pharmacother. 9(3), 499-508 (2008).